CN115884984A - 用于治疗肝纤维化的结合物和方法 - Google Patents

用于治疗肝纤维化的结合物和方法 Download PDF

Info

Publication number
CN115884984A
CN115884984A CN202080091946.7A CN202080091946A CN115884984A CN 115884984 A CN115884984 A CN 115884984A CN 202080091946 A CN202080091946 A CN 202080091946A CN 115884984 A CN115884984 A CN 115884984A
Authority
CN
China
Prior art keywords
group
sirna
compound
formula
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080091946.7A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·海斯
理查德·J·霍兰德
马克·伍德
艾伦·D·马丁
克莉丝汀·伊索
玛格丽特·施瓦兹
叶欣
爱丽丝·霍伊·拉姆·李
克里斯多夫·贾斯汀·帕塞特卡
大卫·克罗
史蒂文·泰勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gainawan Science Co ltd
Original Assignee
Gainawan Science Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gainawan Science Co ltd filed Critical Gainawan Science Co ltd
Publication of CN115884984A publication Critical patent/CN115884984A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01051—3 (or 17)-Beta-hydroxysteroid dehydrogenase (1.1.1.51)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202080091946.7A 2019-12-06 2020-12-07 用于治疗肝纤维化的结合物和方法 Pending CN115884984A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944963P 2019-12-06 2019-12-06
US62/944,963 2019-12-06
PCT/US2020/063617 WO2021113820A1 (en) 2019-12-06 2020-12-07 Conjugates and methods for treating liver fibrosis

Publications (1)

Publication Number Publication Date
CN115884984A true CN115884984A (zh) 2023-03-31

Family

ID=76222671

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080091946.7A Pending CN115884984A (zh) 2019-12-06 2020-12-07 用于治疗肝纤维化的结合物和方法

Country Status (12)

Country Link
US (1) US20220387600A1 (https=)
EP (1) EP4069276A4 (https=)
JP (1) JP2023505434A (https=)
KR (1) KR20220112788A (https=)
CN (1) CN115884984A (https=)
AU (1) AU2020398708A1 (https=)
BR (1) BR112022010613A2 (https=)
CA (1) CA3163911A1 (https=)
IL (1) IL293560A (https=)
MX (1) MX2022006846A (https=)
NZ (1) NZ788988A (https=)
WO (1) WO2021113820A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119143818A (zh) * 2024-06-13 2024-12-17 广州必贝特医药股份有限公司 用于靶向递送寡核苷酸药物的化合物、缀合物及其应用
WO2025001680A1 (zh) * 2023-06-30 2025-01-02 上海维申医药有限公司 新型GalNAc的靶向递送片段及其制备和应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3020585A1 (en) * 2016-04-11 2017-10-19 Arbutus Biopharma Corporation Targeted nucleic acid conjugate compositions
CN118234862A (zh) * 2021-09-08 2024-06-21 阿利戈斯治疗公司 经修饰的短干扰核酸分子(siNA)及其用途
WO2024175062A1 (zh) * 2023-02-23 2024-08-29 大睿生物医药科技(上海)有限公司 调控KHK基因活性的dsRNA分子
US20240352464A1 (en) * 2023-03-07 2024-10-24 Aligos Therapeutics, Inc. Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3020585A1 (en) * 2016-04-11 2017-10-19 Arbutus Biopharma Corporation Targeted nucleic acid conjugate compositions
MX2019012280A (es) * 2017-04-11 2020-01-23 Arbutus Biopharma Corp Composiciones dirigidas.
WO2019051257A2 (en) * 2017-09-11 2019-03-14 Arbutus Biopharma Corporation METHODS OF TREATING HEPATITIS B TYPE INFECTIONS
AU2019239971B2 (en) * 2018-03-21 2025-09-11 Regeneron Pharmaceuticals, Inc. 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof
EP3873530A4 (en) * 2018-11-02 2022-11-09 Genevant Sciences GmbH THERAPEUTIC PROCESSES

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025001680A1 (zh) * 2023-06-30 2025-01-02 上海维申医药有限公司 新型GalNAc的靶向递送片段及其制备和应用
CN119143818A (zh) * 2024-06-13 2024-12-17 广州必贝特医药股份有限公司 用于靶向递送寡核苷酸药物的化合物、缀合物及其应用
WO2025255972A1 (zh) * 2024-06-13 2025-12-18 广州必贝特医药股份有限公司 用于靶向递送寡核苷酸药物的化合物、缀合物及其应用

Also Published As

Publication number Publication date
IL293560A (en) 2022-08-01
NZ788988A (en) 2026-02-27
US20220387600A1 (en) 2022-12-08
EP4069276A4 (en) 2025-10-08
EP4069276A1 (en) 2022-10-12
BR112022010613A2 (pt) 2022-08-16
JP2023505434A (ja) 2023-02-09
CA3163911A1 (en) 2021-06-10
AU2020398708A1 (en) 2022-07-14
WO2021113820A1 (en) 2021-06-10
KR20220112788A (ko) 2022-08-11
MX2022006846A (es) 2022-10-21

Similar Documents

Publication Publication Date Title
JP7588855B2 (ja) 治療方法
CN115884984A (zh) 用于治疗肝纤维化的结合物和方法
CN113164509B (zh) 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法
CN110741087B (zh) 靶向组合物
KR20220053599A (ko) 핵산을 전달하기 위한 개선된 지질 나노입자
US20230076803A1 (en) Compound and drug conjugate, and preparation method and use thereof
JP2022515503A (ja) 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
AU2020280439A1 (en) Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
AU2017279512A1 (en) 5'-cyclo-phosphonate modified nucleotides
CN112105625A (zh) 核苷酸前体、核苷酸类似物以及含其的寡聚化合物
JP2022533419A (ja) 核酸、薬物組成物及び複合体ならびに調製方法と使用
JP2021511029A (ja) Ｓｒｅｂｐ１を標的とするアンチセンスオリゴヌクレオチド
JP2026506685A (ja) プログラム細胞死リガンド１遺伝子の発現を抑制するためのｓｉＲＮＡ、そのコンジュゲート及び医薬組成物並びにその用途
JP7668032B2 (ja) 先端巨大症を処置するためのコンジュゲート及び方法
JP2026503499A (ja) 修飾されたヌクレオシド単量体及び二本鎖リボ核酸
WO2023208106A1 (zh) 具有肝靶向递送效应的化合物及其寡聚核苷酸缀合物
WO2022266132A1 (en) Treatment of plin1 related diseases and disorders
WO2025261378A1 (zh) 一种修饰的核苷化合物及其在寡核苷酸中的应用
NZ787057A (en) Targeted nucleic acid conjugate compositions
CN121450643A (zh) 一种靶向AGT的双链siRNA、其缀合物及其用途
BR112018070956B1 (pt) Composto, composição farmacêutica e uso de um composto

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination